288569-60-8

Basic information

• Product Name: 1-cyanocyclopropyl 4-methylbenzenesulfonate
• Synonyms: 1-cyanocyclopropyl 4-methylbenzenesulfonate;1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]cyclopropanecarbonitrile;(1-Cyanocyclopropyl)methyl 4-methylbenzenesulfonate
• CAS NO: 288569-60-8
• Molecular Formula: C₁₂H₁₃NO₃S
• Molecular Weight: 237.27494
• Mol File: 288569-60-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 432.0±18.0 °C(Predicted)
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-cyanocyclopropyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyanocyclopropyl 4-methylbenzenesulfonate(288569-60-8)
• EPA Substance Registry System: 1-cyanocyclopropyl 4-methylbenzenesulfonate(288569-60-8)

Safety Data

• Hazardous Substances Data: 288569-60-8(Hazardous Substances Data)

Usage

General Description

1-cyanocyclopropyl 4-methylbenzenesulfonate is an organic compound with the chemical formula C11H9NO2S. It is a white crystalline solid that is commonly used as a chemical reagent in organic synthesis. 1-cyanocyclopropyl 4-methylbenzenesulfonate is known for its ability to react with nucleophiles and undergo substitution reactions. It is often used in the preparation of various pharmaceuticals and agrochemicals. Additionally, it is also used as a building block in the synthesis of other organic compounds. Despite its potential applications, 1-cyanocyclopropyl 4-methylbenzenesulfonate should be handled and used with caution due to its toxic and irritant nature.

Upstream product

• 4124-41-8 p-toluenesulfonylanhydride 
• 98730-77-9 1-hydroxymethyl-cyclopropanecarbonitrile 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1162670-03-2 1-(4-chloro-2-formyl-phenoxymethyl)-cyclopropanecarbonitrile 

Relevant articles and documents

XANTHINE CB1 INHIBITORS

Disclosed are compounds having structural formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).

Novel Compounds

The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediated disease state.

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.